# Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

> **NCT00869401** · PHASE1,PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 217 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** dasatinib
- **DRUG:** temozolomide
- **OTHER:** placebo
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00869401
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2014-10
- **Final completion:** 2019-11-15
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2020-02-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00869401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00869401, "Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00869401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*